Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship

Hideaki Kato a, b, *, Hiroyuki Shimizu c, Yasushi Shibue d, Tomohiro Hosoda e, Keisuke Iwabuchi f, Kotaro Nagamine g, Hiroki Saito h, Reimin Sawada i, Takayuki Oishi j, Jun Tsukiji k, Hiroyuki Fujita l, Ryosuke Furuya m, Makoto Masuda n, Osamu Akasaka o, Yu Ikeda p, Mitsuo Sakamoto c, Kazuya Sakai p, Munehito Uchidama q, Hiroki Watanabe s, Nobuhiro Yamaguchi t, Ryoko Higa u, Akiko Sasaki v, Katsuki Tanaka w, Yukitoshi Toyoda x, Shinsuke Hamanaka y, Naoki Miyazawa z, Atsuko Shimizu k, Fumie Fukase l, Shunsuke Iwai p, Yuko Komase y, Tsutomu Kawasaki z, Isao Nagata aa, Yusuke Nakayama ab, Tetsuhiro Takei ac, Katsuo Kimura ad, Reiko Kunisaki ae, Makoto Kudo af, Ichiro Takeuchi af, Hideaki Nakajima b

a Infection Prevention and Control Department, Yokohama City University Hospital, Japan
b Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan
c Department of Clinical Laboratory Medicine, Fujisawa City Hospital, Japan
d Department of Infectious Diseases, Yokohama City Minato Red Cross Hospital, Japan
e Department of Infectious Diseases, Kawasaki Municipal Kawasaki Hospital, Japan
f Department of General Medicine, Kanagawa Prefectural Ashigarakami Hospital, Japan
g Department of Surgery, Yokosuka City Hospital, Japan
h Department of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Japan
i Department of Cardiology, Japanese Red Cross Hadano Hospital, Japan
j Department of Infection Control and Prevention, Saiseikai Yokohamashi Tobu Hospital, Japan
k Department of Prevention and Infection Control, Yokohama City University Medical Center, Japan
l Infection Control Committee, Saiseikai Yokohama Nanbu Hospital, Japan
m Department of Critical Care and Emergency Medicine, National Hospital Organization Yokohama Medical Center, Japan
n Department of Respiratory Medicine, Fujisawa City Hospital, Japan
o Emergency Medical Center, Fujisawa City Hospital, Japan
p Department of Emergency Medicine, Yokohama City University School of Medicine, Japan
q Department of Pulmonology, Yokohama City University Graduate School of Medicine, Japan
r Department of Respiratory Medicine, Yokosuka City Hospital, Japan
s Nursing Department, Japanese Red Cross Hadano Hospital, Japan
t Department of Gastroenterology, Japanese Red Cross Hadano Hospital, Japan
u Department of Emergency and Critical Care Medicine, Saiseikai Yokohamashi Tobu Hospital, Japan
v Department of Pulmonary Medicine, Saiseikai Yokohamashi Tobu Hospital, Japan
w Department of Respiratory Medicine, Saiseikai Yokohama Nanbu Hospital, Japan
x Infection Control Team, National Yokohama Medical Center, Japan
y Department of Respiratory Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Japan
z Department of Respiratory Medicine, Yokohama City Minato Red Cross Hospital, Japan
aa Intensive Care Unit, Yokohama City Minato Red Cross Hospital, Japan
ab Emergency Department, Yokohama City Minato Red Cross Hospital, Japan
ac Department of Neurology, Yokohama City University Medical Center, Japan
ad Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Japan
ae Respiratory Disease Center, Yokohama City University Medical Center, Japan
af Kanagawa Disaster Medical Assistance Team, Japan
ag Advanced Emergency Medical Service Center, Yokohama City University Medical Center, Japan

* All authors meet the ICMJE authorship criteria.
* Corresponding author. Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan.
E-mail address: ekato@yokohama-cu.ac.jp (H. Kato).
A novel coronavirus disease (COVID-19) caused by SARS-CoV-2 in early 2020 abruptly spread within three months from the east-Asian countries to other parts of the world. In Japan, the first outbreak of COVID-19 was reported in a giant cruise ship called the Diamond Princess. This cruise ship had a gross tonnage of 115,000 tons with a maximum capacity of 2706 passengers and 1100 operating staffs. The cruise started on January 20, 2020, from Yokohama stopped at Kagoshima (Southern Japan), Hong Kong, Da Nan and Chan May (Vietnam), Ha Long bay (Vietnam), Keelung (Taiwan) and Okinawa (Southern Japan). At the cruise ship’s arrival at Yokohama near the Tokyo metropolitan area early morning on February 3, 2020, 10 people were confirmed to be positive for SARS-CoV-2 [1]. Finally, 3618 individuals were screened out of 3711 individuals (2666 guests and 1045 crew) on board on February 3; in total, 696 individuals (19.2%) were confirmed positive for SARS-CoV-2 [2]. A Japanese quarantine officer, the Disaster Medical Assistance Team, and a small number of infection control specialists were dispatched to quarantine the individuals on board to assess the health status of the individuals on the cruise ship. Hundreds of asymptomatic passengers who were confirmed or suspected to be infected with SARS-CoV-2 were kept isolated on the cruise ship, and they were allowed to disembark from the cruise ship only after the quarantine observation for two weeks. Disembark of 3711 individuals on the cruise ship was completed on March 1. Meanwhile, individuals who required medical care, mainly those with severe symptoms during February 3 and March 1, were transferred to local hospitals near the Yokohama city area, which is the largest city in the Kanagawa Prefecture for medical care [3]. In this study, we describe the clinical conditions, treatment, and the clinical course of the patients positive for SARS-CoV-2 who were transferred from the Diamond Princess cruise ship for further medical care to the participating hospitals in this study.

The patients’ vital signs, laboratory data, chest radiographs, or computed tomography (CT) findings at the time of admission and treatment, and the data on the clinical course and prognosis were collected using case report forms. Case report forms were collected on March 11 and March 19, 2020. The clinical findings of the patients without pneumonia were compared with those of the patients with pneumonia. The patient race was determined based on the estimation of his/her ancestor by each participating physician.

Patient severity was defined according to World Health Organization criteria [4]. No patient was excluded because of bacterial or any other type of viral pneumonia by additional laboratory tests and sputum culture. The specimens for reverse transcription PCR for SARS-CoV-2 was obtained first when the patients were on the Diamond Princess cruise ship or otherwise at the time of transfer to the hospitals, and were submitted to the municipal or governmental laboratories and examined according to the instructions of the National Institute of Infectious Diseases (version 2.8 and previous versions). The use of drugs unapproved for the treatment of COVID-19 or severe lower respiratory tract infection in Japan was approved by the clinical ethical committee at each institution. This study was approved by the ethics committees at the Yokohama City University Hospital (approval number: B200200047) and the participating hospitals. Continuous data were presented as medians, and interquartile ranges were presented as (Q1–Q3). Categorical data were presented as numbers and percentages. Data were analyzed using a two-tailed Mann–Whitney U test for comparisons of continuous variables among two or three groups and by Fisher’s exact test for comparisons of categorical data. Statistical analyses were performed with Prism 8 (GraphPad Software, San Diego, CA, USA). P-values of <0.05 were considered statistically significant.

Seventy patients positive for SARS-CoV-2 were included in our study. The dates of onset of COVID-19 in these patients are summarized in Fig. 1 (date of onset among six patients were missing). The predisposing conditions, general status, vital signs at admission, and laboratory data are shown in Table 1. The median age of the patients was 67 years; 67.1% of the patients were males, and 80% of the patients were Asians. The predisposing conditions were diabetes (24.3%) and hypertension (22.9%). Very few patients had active malignancy and renal failure. No one had HIV infections and liver dysfunction. The major symptoms of all the 70 patients were fever (64.3%), cough (54.3%), and general fatigue (24.3%). The median duration from onset of COVID-19 to admission was 4 days (2–6 days). Patients with pneumonia had significantly higher body temperatures than those without pneumonia (37.7 °C vs. 36.7 °C, P < 0.001). Heart rates (88 vs. 78/min) and respiratory rates (20 vs. 16/min) were significantly higher in the patients with pneumonia. Further, 14.3% of the patients with or without pneumonia required
supplemental oxygen at the time of admission. Laboratory data taken at admission showed that the serum albumin levels were lower in patients with pneumonia than in those without pneumonia (3.9 vs. 4.2 g/dL), whereas the levels of lactate dehydrogenase (LDH) (265 vs. 206 U/L) and aspartate aminotransferase (AST) (36 vs. 26 U/L) were significantly higher in the patients with pneumonia than in those without pneumonia. The peripheral lymphocyte count was significantly lower in the patients with pneumonia than in those without pneumonia (957 vs. 1461/µL). C-reactive protein (CRP) levels were significantly higher in the patients with pneumonia than in those without pneumonia (3.7 vs. 0.4 mg/dL). Among the 43 patients with pneumonia, consolidation on chest CT was found in 27.9% and ground-glass opacity (GGO) was found in 97.7% of the patients with pneumonia. Notably, GGOs were bilateral (93.0%), multifocal (74.4%), and peripheral dominant (90.7%).

Regarding treatments and clinical courses, the median observation period was 16 days (12–21 days) among all cases included in this study. Forty-one (58.6%) patients including 34 with pneumonia and 7 without pneumonia were administered antibiotics. The selected antibiotics are shown in Table 2. Ceftriaxone and azithromycin were mostly chosen as the antibiotics for the initial treatment. With regard to the anti-viral drugs, the following neuraminidase inhibitors were administered in 14 patients: oseltamivir (n = 6), peramivir (n = 4), baloxavir (n = 1), and a combination of oseltamivir and baloxavir (n = 3). LPV/r was administered to 24 patients. Two patients with pneumonia were treated with a combination of neuraminidase inhibitors, LPV/r, and ribavirin. In addition, ciclesonide inhalation, which was suggested to have anti-coronavirus activity, was administered in 8 patients with pneumonia. Fourteen patients with pneumonia required mechanical ventilation; among them, 2 patients required veno-venous extracorporeal membrane oxygenation (V–V ECMO). Three patients with pneumonia remained intubated for 19–25 days on the mechanical ventilator at the time of end of observation. The remaining 7 patients were successfully extubated after a median of 12 days (6–18 days) on mechanical ventilation. The median duration of hospital admission was 18 days (16–20 days) in 48 patients who were discharged from hospitals during the study period. The median duration between the first positive PCR result and the first negative PCR confirmation was 15 days (10–18 days).

Notably, the severity of this disease in the patients transferred from the cruise ship was very high compared with that previously reported in the general population in China [5,6]. The one reason was attributed to advanced age [6]. Generally, the average age of the Japanese passengers on Asian cruise ships is reported to be 57 years [7]. Most of the individuals on the Diamond Princess on February 5, 2020, were aged ≥60 years of age [2]. The crowded and closed environment on the cruise ship was possibly a suitable condition for high transmission of respiratory infections [8]. In these individuals with COVID-19, the severity of the disease varied widely from almost asymptomatic to critical cases such as those requiring ventilator support. The initial symptoms—fever, dry cough and general fatigue, were quite nonspecific. The severity of the disease depended on the presence of pneumonia. The findings of our study show that it is critical to differentiate patients with pneumonia from those without pneumonia to predict their clinical course and treatment plan. High LDH and AST levels possibly reflect the interstitial lung inflammation due to COVID-19. Low lymphocyte count and high LDH level were considered key to predict pneumonia in patients with COVID-19 because their levels serve as predictors of severe conditions [9]. The bilateral GGOs was helpful for diagnosing COVID-19. Chest CT is more sensitive than chest radiographs, and the bilateral GGOs in the lower lung lobes are reported to be specific to COVID-19 [10,11]. We suggest that chest CT should be considered if a patient is suspected to have pneumonia due to COVID-19 but PCR findings were still under examination. No treatment regimen has yet been established for the treatment of COVID-19. In the participating hospitals, unapproved
drugs were used for the treatment. Treatment with LPV/r, neuraminidase inhibitors, cilastone inhalation, favipiravir and rivabirin were attempted. Our colleagues reported that cilastone inhalation is effective for the treatment of COVID-19 [12,13].

Our study has several limitations. First, data were collected from the case report forms from each attending physician in the participating hospitals. The diagnosis and treatment were dependent on the clinical decision of each physician. Second, this study was descriptive and we did not properly evaluate the efficacies of the drugs or the supportive care. Further studies should be performed to assess the efficacy of these drugs for the treatment of severe cases of COVID-19. Third, we were not able to investigate all cases of COVID-19 on the Diamond Princess cruise. The environment inside the cruise ship is suitable for high transmission of respiratory infections [8]. Because individuals with severe conditions during an outbreak are possibly transferred to nearby local hospitals, managing patients during an outbreak is a big challenge to local medical systems. We believe that our findings of patients with COVID-19 during its outbreak on a cruise ship can help to manage a large number of patients infected within a short period of time.

Table 1

| Predisposing conditions and laboratory data of the study patients. | All patients (N = 70) | Patients with pneumonia (n = 43) | Patients without pneumonia (n = 27) | P-value |
|---|---|---|---|---|
| **Age (years)** | 67 (62–71) | 69 (65–72) | 65 (54–71) | 0.547 |
| **Male sex** | 47 (67.1%) | 32 (74.4%) | 15 (55.6%) | 0.122 |
| **Race** | | | | |
| Japanese | 32 (45.7%) | 23 (53.5%) | 9 (33.3%) | 0.140 |
| Asian (excluding Japanese) | 24 (34.3%) | 13 (30.2%) | 11 (40.7%) | 0.441 |
| European/American | 14 (20.0%) | 7 (16.3%) | 7 (25.9%) | 0.368 |
| **Underlying conditions** | | | | |
| Diabetes | 17 (24.3%) | 12 (27.9%) | 5 (18.5%) | 0.409 |
| Hypertension | 16 (22.9%) | 13 (30.2%) | 3 (11.1%) | 0.083 |
| Cardiovascular disease | 1 (1.4%) | 1 (2.3%) | 0 (0%) | 0.054 |
| Malignancy | 1 (1.4%) | 0 (0%) | 1 (3.7%) | 0.379 |
| Cerebrovascular disease | 1 (1.4%) | 1 (2.3%) | 0 (0%) | 0.054 |
| COPD | 2 (2.9%) | 1 (2.3%) | 1 (3.7%) | 0.379 |
| Chronic renal disease | 1 (1.4%) | 1 (2.3%) | 0 (0%) | 0.054 |
| **General status and vital signs** | | | | |
| Body temperature (°C) | 37.3 (36.7–38.1) | 37.7 (37.1–38.5) | 36.7 (36.4–37.1) | <0.001 * |
| Heart rate (/min) | 84 (77–92) | 88 (80–92) | 78 (70–85) | <0.001 * |
| Systolic blood pressure (mmHg) | 134 (124–148) | 133 (124–150) | 136 (122–145) | 0.761 |
| Respiratory rate (/min) | 18 (16–20) | 20 (16–22) | 16 (14–18) | 0.005 * |
| Supplemental oxygen | 10 (14.3%) | 8 (18.6%) | 2 (7.4%) | 0.297 |
| **Major symptoms** | | | | |
| Fever | 45 (64.3%) | 30 (69.8%) | 15 (55.6%) | 0.306 |
| Cough | 38 (54.3%) | 22 (51.2%) | 16 (59.3%) | 0.624 |
| Wet cough | 5 (7.1%) | 4 (7.4%) | 2 (7.4%) | 0.637 |
| General fatigue | 17 (24.3%) | 12 (27.9%) | 5 (18.5%) | 0.409 |
| Shortness of breath | 12 (17.1%) | 9 (20.9%) | 3 (11.1%) | 0.347 |
| Diarrhea | 10 (14.3%) | 6 (14%) | 4 (14.8%) | 1.0 |
| Sputum | 9 (12.9%) | 4 (9.3%) | 5 (18.5%) | 0.292 |
| Appetite loss | 9 (12.9%) | 7 (16.3%) | 2 (7.4%) | 0.466 |
| Sore throat | 8 (11.4%) | 6 (14%) | 2 (7.4%) | 0.472 |
| Headache | 6 (8.6%) | 5 (11.6%) | 1 (3.7%) | 0.394 |
| Myalgia | 3 (4.3%) | 1 (2.3%) | 2 (7.4%) | 0.555 |
| **Laboratory data** | | | | |
| Total protein (g/dL) | 7 (6.7–7.4) | 7 (6.6–7.3) | 7.3 (6.7–7.6) | 0.218 |
| Albumin (g/dL) | 3.9 (3.5–4.2) | 3.9 (3.4–4.1) | 4.2 (3.7–4.6) | 0.001 * |
| LDH (U/L) | 252 (200–358) | 265 (232–392) | 206 (172–266) | 0.001 * |
| AST (U/L) | 29 (25–41) | 36 (25–47) | 26 (22–31) | 0.005 * |
| ALT (U/L) | 26 (20–43) | 32 (21–44) | 20 (18–36) | 0.075 |
| ALP (U/L) | 196 (178–251) | 191 (175–227) | 224 (180–286) | 0.107 |
| BUN (mg/dL) | 15.5 (12.1–20.0) | 15.5 (12.4–19.1) | 15.5 (12.0–22.5) | 0.924 |
| Serum creatinine (mg/dL) | 0.81 (0.67–0.97) | 0.86 (0.66–1.06) | 0.74 (0.67–0.82) | 0.104 |
| Total bilirubin (mg/dL) | 0.6 (0.4–0.7) | 0.6 (0.4–0.7) | 0.6 (0.5–0.7) | 0.649 |
| C-reactive protein (mg/dL) | 2.1 (0.4–5.3) | 3.7 (1.7–7.3) | 4.0 (3.2–11.3) | <0.001 * |
| Bicarbonate (HCO3−, mmol/L) | 240 (230–258) | 239 (225–251) | 257 (238–283) | <0.001 * |
| Lactate level (mmol/L) | 1.2 (0.9–1.2) | 1.2 (1.1–1.3) | 0.9 (0.9–1.3) | 0.198 |
| White blood cell count (/μL) | 5600 (4075–7600) | 5750 (4125–7535) | 5600 (3975–7775) | 0.705 |
| Absolute neutrophil count (/μL) | 3700 (2611–5605) | 4170 (2039–5605) | 2991 (1943–6348) | 0.127 |
| Lymphocyte count (/μL) | 1071 (632–1428) | 957 (796–1195) | 1461 (1092–1912) | 0.003 * |
| Hemoglobin level (g/dL) | 14.5 (13.2–15.4) | 14.0 (13.2–15.4) | 14.7 (13.1–15.7) | 0.785 |
| Platelet count (× 103/μL) | 197 (163–250) | 185 (158–232) | 228 (168–262) | 0.064 |
| Procalcitonin level (ng/mL) | 0.06 (0.04–0.14) | 0.10 (0.05–0.16) | 0.03 (0.02–0.06) | 0.028 |
| Positive urinary ketone | 6 (8.6%) | 6 (14.8%) | 0 (0%) | 0.307 |

* Data are expressed as n (%) or median (interquartile range Q1–Q3). Abbreviations: COPD, chronic obstructive pulmonary disease; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen.

* statistically significant.
time. Assessment of disease severity was crucial to manage a large
number of patients.

Funding

We did not receive any funding support for this study.

Ethical standards

This study was approved by the ethics committee at each
participating institution.

Declaration of Competing Interest

The authors have no conflict of interest to declare.

Acknowledgement

We thank our medical staffs and colleagues who were involved
in caring for the patients from the cruise ship. We sincerely
appreciate our families for supporting our jobs. We also appreciate
the municipal officers of the Yokohama City and the Kanagawa
Prefecture for cooperating with us in managing the patients. The
authors would like to thank Enago (www.enago.jp) for the English
language review.

References

[1] Diamond Princess Updates. https://www.princess.com/news/notices_and_advisories/notices/diamond-princess-update.html; 2020. Feb 6 [cited 2020 Mar 7].
[2] National Institute of Infectious Diseases. Field briefing: Diamond princess COVID-19 cases. 2020. 20 Feb Update. https://www.niid.go.jp/niid/en/2019-ncov-e/9417-covid-dp-fe-02.html. Feb 21. [cited 2020 Mar 7].
[3] Takeuchi I. COVID-19 first stage in Japan - how we treat Diamond princess cruise ship with 3700 passengers? Acute Med Surg 2020;7(1):e506.https://doi.org/10.1002/ams2.506.
[4] World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020. Interim guidance 13 March 2020,https://apps.who.int/iris/handle/10665/331446. Mar 13 [cited Mar 19].
[5] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054 e62. https://doi.org/10.1016/S0140-6736(20)30566-3.
[6] Guan WJ, Ni ZY, Hu Y, Fan G, Liu Y, Liu Z, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708 e20. https://doi.org/10.1056/NEJMoa2002032.
[7] Cruise Lines International Association. 2017 Asia cruise report. 2017.https://cruising.org/-/media/research-updates/research/asia-cruise-trends/asia-cruise-trends-2017.pdf. Jul [cited 2020 Mar 7].
[8] Rocklov J, Sjödin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Trav Med 2020.https://doi.org/10.1093/jtm/taaa030. taaa030.
[9] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020:e201585. https://doi.org/10.1001/jama.2020.1585.
[10] Pan F, Ye T, Sun P, Gui S, Liang B, Li Lingli, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology 2020;200370. https://doi.org/10.1148/radiol.2020200370.
[11] Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020:200343. https://doi.org/10.1148/radiol.2020200343.
[12] Nakajima K, Ogawa F, Sakai K, Uchiyama M, Oyama Y, Kato H, et al. A case of coronavirus disease 2019 treated with ciclesonide. J Infect Chemother 2020. https://doi.org/10.1016/j.jiac.2020.04.007 [in press].
[13] Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishita T. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases. J Infect Chemother 2020. https://doi.org/10.1016/j.jiac.2020.04.007 [in press].

Table 2

Treatments and supportive care for the study patients.

| Antibiotics                                      | Total (N – 70) | Patients with pneumonia (n – 43) | Patients with mild illness (n – 27) |
|-------------------------------------------------|---------------|---------------------------------|-----------------------------------|
|ampicillin/amoxicillin + BLI                     | 3 (4.3%)      | 2 (7.0%)                        | 1 (3.7%)                          |
ceftriaxone                                      | 6 (8.6%)      | 5 (11.6%)                       | 1 (3.7%)                          |
ceftriaxone + levofloxacin                      | 7 (10.0%)     | 7 (16.3%)                       | 0 (0%)                            |
cefepime + azithromycin                         | 10 (14.3%)    | 9 (20.9%)                       | 1 (3.7%)                          |
meropenem + azithromycin                        | 2 (2.9%)      | 1 (2.3%)                        | 1 (3.7%)                          |
levofloxacin                                     | 6 (8.6%)      | 5 (11.6%)                       | 1 (3.7%)                          |
azithromycin                                    | 7 (10.0%)     | 5 (11.6%)                       | 2 (7.4%)                          |
no antibiotic was administered                   | 29 (41.4%)    | 9 (20.9%)                       | 20 (74.1%)                        |
antiviral drugs                                  |               |                                 |                                   |
lopinavir/ritonavir                              | 24 (34.2%)    | 23 (53.5%)                      | 1 (3.7%)                          |
neuraminidase inhibitor                         | 14 (20.0%)    | 13 (30.2%)                      | 1 (3.7%)                          |
ciclesonide                                      | 8 (11.4%)     | 8 (18.6%)                       | 0 (0%)                            |
favipiravir                                      | 3 (4.3%)      | 3 (7.0%)                        | 0 (0%)                            |
rivabrin                                         | 2 (2.9%)      | 2 (4.7%)                        | 0 (0%)                            |
other supportive care                            |               |                                 |                                   |
mechanical ventilation                           | 14 (20.0%)    | 14 (32.6%)                      | 0 (0%)                            |
steroid pulse therapy                            | 2 (2.9%)      | 2 (4.7%)                        | 0 (0%)                            |
intravenous immunoglobulin                       | 6 (8.6%)      | 6 (14.0%)                       | 0 (0%)                            |
v-vcemo                                          | 2 (2.9%)      | 2 (4.7%)                        | 0 (0%)                            |

Data are expressed as n (%).

Abbreviations: BLI, β-lactamase inhibitors; V-V ECMO, veno-venous extracorporeal membrane oxygenation.